High-throughput RNA sequencing (RNA-Seq) promises a complete annotation and quantification of all genes and their isoforms across samples. Because sequencing reads from this new technology are shorter than transcripts from which they are derived, expression estimation with RNA-Seq requires increasingly complex computational methods. In recent years, a number of expression quantification methods have been published from both public and commercial sources. Here we presented an overview of these attempts on quantifying gene expression. We then defined a set of criteria and compared the performance of several programs based on these criteria, and we further provided advices on selecting suitable tools for different biological applications.
INTRODUCTION
Next-generation sequencing (NGS) platforms have been widely available recently [1] . A massively parallel sequencing technology termed RNA-Seq has made it possible to sequence cDNA derived from cellular RNA [2] . Compared to previous technologies for gene mapping with their alternative isoforms and expression detection across diverse cell types, RNA-Seq is more promising in building a complete transcriptome across cell types and states.
Recently, many studies have applied RNA-Seq to various biological and medical research. Quantification of alternative splicing in tissues [3] , discovery of new fusion genes in cancer [4] , and new transcript identification [5] have all benefited from this new technology. To fully enable RNA-Seq technology to solve biological problems, powerful computational tools are required. In the past two years, software applications for RNA-Seq analysis have been flooding the market from public domains as well as commercial organizations. How to identify and use the suitable tools for RNA-Seq analysis becomes critical.
Here we focus on the computational methods for gene expression quantification by RNA-Seq. Using Google Scholar citation, as shown in Table 1 , we selected two popular analysis pipelines from public domains and two workflows from commercial products. We applied them to a human gastric cancer RNA-Seq dataset consisting of 40 million paired-end 100-base reads from Illumina Hiseq 2000 platform. We also compared RNA-Seq quantification with Affy quantification using Affymetrix human genome U133A2.0 array on the same human gastric cancer sample.
RESULTS

Descriptions of Chosen RNA-Seq Quantification Tools
In general, current transcriptome assembly tools belong to either a reference-based strategy or de novo strategy or both [6] . When a reference genome is available, RNASeq reads are firstly mapped by a splice-aware aligner and an output alignment file is used as the input file of a transcriptome assembly tool. Two reference-based transcriptome assembly tools, Cufflinks [7] and Scripture [5] , are selected according to their average citation numbers per month (CPM) calculated by the total number of citations retrieved from Google Scholar divided by the number of months since their publication date. Another tool Alexa-seq [8] is not chosen because of both the small CPM 1.6 and difficulties to install it on a Linux server. Cufflinks can be launched in two modes using options -G/--GTF and -g/--GTF-guide. Both modes need a reference GFF annotation file from mainly three data sources Ensembl (www.ensembl.org), NCBI (www.ncbi.nlm.nih.gov) and UCSC (http://genome.ucsc.edu/). The first option -G/--GTF tells Cufflinks to use the supplied reference annotation to estimate isoform expression. The latter option -g/--GTFguide tells Cufflinks to use the supplied reference annotation to guide RABT assembly [9] . However, Scripture is a method for transcriptome reconstruction that relies solely on RNA-Seq reads and an assembled genome to build a transcriptome ab initio.
Array Studio is a suite of tools developed by OmicSoft (www.omicsoft.com) in which an RNA-Seq analysis workflow is provided. Expression quantification analysis of RNA-Seq can be performed in two ways by mapping to either genome or transcriptome.
CLC Genomics Workbench is a Desktop application for NGS analysis developed by CLCbio (www.clcbio.com).
Summaries of Results of RNA-Seq Analysis
An in-house RNA-Seq dataset was used and six types of results were generated. For Cufflinks, two results from both -G/--GTF and -g/--GTF-guide modes which are denoted by Cuff.(-G) and Cuff.(-g). For Array Studio, by against both genome and transcriptome, two results were shown and denoted by OMIC(G) and OMIC(T). The result of CLC Genomics Workbench was CLC GW, and the last result is from Scripture. Summaries about the six results can be found in Tables 2 and 3. Note that CLC Genomics Workbench only gives gene information, so genes with only one transcript were counted.
There are some differences between Tables 2 and 3. In In Table 3 , Affy data were processed using Affymetrix Expression Console. Most of genes in Affy are included by RNA-Seq results. Cufflinks adopts a naming mechanism when -g/--GTF-guide option is turned on, so the number of common genes is very small when merging two datasets according gene names. Actually, we showed that 77% of results of Cuff(-g) can reflect (i.e., match or include) 100% of that of Cuff(-G).
Comparisons between RNA-Seq and Affy in Terms of Expression Values
There are always three types of expression values used in the RNA-Seq analysis, RPKM/TPKM, TPM and naïve counts. Because Affy presents expression values on the gene level, only expression values of RNA-Seq on the gene level were shown in Table 3 .
In 
Comparisons between RNA-Seq and Public Annotations for Gene Structures
In this section, results of RNAseq analysis were assessed from the perspective of the linear structure of genomic 
CONCLUSION
In this article, we have shown the evaluation results of a set of public and commercial tools for gene expression quantification by RNA-Seq. Because of rapid improvements in RNA-Seq data generation, more efforts need to be done in the areas of transcriptome analysis, mutation detection, and fusion identification. New questions will continue to emerge and novel programs will evolve. The tool evaluation needs to keep up with the pace of these changes in order to apply RNA-Seq technologies to drug discovery and development.
